|
|
6370 Nancy Ridge Drive, Suite 112 San Diego, CA 92121 USA phone:858-657-0287 fax:858-657-0288
|
|
| Symbol |
MIIS |
| Exchange |
.OB |
| Founded |
0 |
| Employees |
|
|
|
| www.microislet.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Transplantation therapy for patients with diabetes. |
 |
| Management |
| Michael J. Andrews, President & Chief Executive Officer; Brian Conn, Vice President of Finance and Chief Financial Officer; Amaresh Basu, Ph.D., Vice-President, Research & Development
|
| |
|
|
|
|
|
|
|
| Keywords |
| Diabetes, blood sugar, diabetic, metabolic, insulin, insulin, islet cells |
|
|
|
| Description |
|
MicroIslet Inc. is a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes.
MicroIslet has licensed several technologies from Duke University Medical Center that were developed over the last decade for the isolation, culture, storage and encapsulation of insulin-producing porcine islet cells. These proprietary methods may enable diabetic patients to become free from insulin injections. MicroIslet's ultimate goal is to offer a solution towards a cure for diabetes worldwide. |
 |
| Products / Services |
MicroIslet-P
|
 |
| Technology / Differentiation |
| MicroIslet-P will be a ready-to-use formulation that will require very little preparation by the transplant surgeon. MicroIslet's technologies are designed to improve microencapsulated islet cell viability and functionality at several points in the preparation of this suspension. They believe their cell handling techniques substantially increase the longevity and functionality of the encapsulated islet cells. |
 |
| Market / Customers |
There are 11.1 million diabetes sufferers in the United States and the Center for Disease Control estimates that another 6 million cases are undiagnosed.
|
 |
|
|
|
|
|
|